^
Association details:
| Biomarker: | PD-1 expression |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + bempegaldesleukin (NKTR-214) (IL-2 stimulant, CD122 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Published date:
06/16/2022
Excerpt:
...we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma...Results of our exploratory investigation of predictive biomarkers show...PD-1 expression correlate with improved ORR...
DOI:
10.1038/s41467-022-30874-8
Trial ID:
